REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - PDMR Dealing

MaxCyteAnnouncement

11/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240611:nRSK9400Ra&default-theme=true

RNS Number : 9400R  MaxCyte, Inc.  11 June 2024

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

PDMR Dealing

 

ROCKVILLE, MD, June 12, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative, cell-based
research, announces that between 7 June 2024 and 10 June 2024, Maher Masoud,
President and Chief Executive Officer of the Company, using personal funds,
purchased 100,000 shares on the open market of common stock in the Company
("Common Stock"). The 100,000 shares of Common Stock were purchased at an
average price of $4.8907 per Common stock.

 

Following the purchase of Common Stock, Maher Masoud holds a total of 100,000
Common Stock representing approximately 0.1 percent of the issued share
capital of the Company. Maher Masoud holds a further 1,074,200 options over
Common Stock and 400,000 performance stock units.

 

MaxCyte Contacts:

 

 US IR Adviser

 Gilmartin Group                               +1 415-937-5400

 David Deuchler, CFA                           ir@maxcyte.com (mailto:ir@maxcyte.com)

 Nominated Adviser and Joint Corporate Broker

 Panmure Gordon                                +44 (0)20 7886 2500

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser                                 +44 (0)203 709 5700

 ICR Consilium                                 maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 Mary-Jane Elliott

 Chris Welsh

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology, as
well as technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com
(https://maxcyte.com/) and follow us on Twitter
(https://twitter.com/MaxCyte_info) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Maher Masoud

 2    Reason for the notification

 a)   Position/status                                              President, CEO and Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common Stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Purchase of common stock

 c)   Price(s) and volume(s)

                                                                                     Purchase Price(s) range  Volume(s)
                                                                                     $4.84-$4.95              29,557

 d)   Aggregated information

      - Aggregated volume                                          29,557

      - Price                                                      $4.866

 e)   Date of the transaction                                      7 June 2024

 f)   Place of the transaction                                     USStock Exchange, Nasdaq

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Maher Masoud

 2    Reason for the notification

 a)   Position/status                                              President, CEO and Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common Stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Purchase of common stock

 c)   Price(s) and volume(s)

                                                                                     Purchase Price(s) range  Volume(s)
                                                                                     $4.77-$5.00              70,443

 d)   Aggregated information

      - Aggregated volume                                          70,443

      - Price                                                      $4.9011

 e)   Date of the transaction                                      10 June 2024

 f)   Place of the transaction                                     USStock Exchange, Nasdaq

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHZFLBFZQLEBBQ